Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8011963,Renal clearance,"Renal clearance values of S-STL were significantly reduced from 33.7 +/- 6.0 to 28.9 +/- 5.6 ml min-1 kg-1 for administration as racemate and pure enantiomer, respectively.",Stereospecific evaluation of sotalol pharmacokinetics in a rat model: evidence suggesting an enantiomeric interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011963/),[ml] / [kg·min],33.7,5414,DB00489,Sotalol
,8011963,Renal clearance,"Renal clearance values of S-STL were significantly reduced from 33.7 +/- 6.0 to 28.9 +/- 5.6 ml min-1 kg-1 for administration as racemate and pure enantiomer, respectively.",Stereospecific evaluation of sotalol pharmacokinetics in a rat model: evidence suggesting an enantiomeric interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011963/),[ml] / [kg·min],28.9,5415,DB00489,Sotalol
,16949884,Area under the % effect-time curve,"Area under the % effect-time curve (% min) was 714+/-214 in Healthy/Placebo, 256+/-249 in Arthritis/Placebo, 1534+/-367 in Healthy/Statin, and 1713+/-393 in Arthritis/Statin.","Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949884/),%·min,714,8258,DB00489,Sotalol
,16949884,Area under the % effect-time curve,"Area under the % effect-time curve (% min) was 714+/-214 in Healthy/Placebo, 256+/-249 in Arthritis/Placebo, 1534+/-367 in Healthy/Statin, and 1713+/-393 in Arthritis/Statin.","Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949884/),%·min,256,8259,DB00489,Sotalol
,16949884,Area under the % effect-time curve,"Area under the % effect-time curve (% min) was 714+/-214 in Healthy/Placebo, 256+/-249 in Arthritis/Placebo, 1534+/-367 in Healthy/Statin, and 1713+/-393 in Arthritis/Statin.","Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949884/),%·min,1534,8260,DB00489,Sotalol
,16949884,Area under the % effect-time curve,"Area under the % effect-time curve (% min) was 714+/-214 in Healthy/Placebo, 256+/-249 in Arthritis/Placebo, 1534+/-367 in Healthy/Statin, and 1713+/-393 in Arthritis/Statin.","Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949884/),%·min,1713,8261,DB00489,Sotalol
,9088581,Cmax,Cmax of sotalol decreased from 1.22 +/- 0.22 mgl-1 (phase 1) to 0.89 +/- 0.29 mgl-1 (phase 2) and increased again to 1.27 +/- 0.18 mgl-1 in phase 3.,Interaction between sotalol and an antacid preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),1/[mgl],1.22,40611,DB00489,Sotalol
,9088581,Cmax,Cmax of sotalol decreased from 1.22 +/- 0.22 mgl-1 (phase 1) to 0.89 +/- 0.29 mgl-1 (phase 2) and increased again to 1.27 +/- 0.18 mgl-1 in phase 3.,Interaction between sotalol and an antacid preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),1/[mgl],0.89,40612,DB00489,Sotalol
,9088581,Cmax,Cmax of sotalol decreased from 1.22 +/- 0.22 mgl-1 (phase 1) to 0.89 +/- 0.29 mgl-1 (phase 2) and increased again to 1.27 +/- 0.18 mgl-1 in phase 3.,Interaction between sotalol and an antacid preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),1/[mgl],1.27,40613,DB00489,Sotalol
,9088581,AUC,"A similar significant change was noted in AUC (15.6 +/- 2.75 mgl-1, 12.3 +/- 3.04 mg h l-1 and 15.0 +/- 2.06 mgl-1) and in the amount of cumulative urinary excretion (79.2 +/- 11.1 mg, 72.1 +/- 11.2 mg and 80.6 +/- 7.9 mg), respectively.",Interaction between sotalol and an antacid preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),1/[mgl],15.6,40614,DB00489,Sotalol
,9088581,AUC,"A similar significant change was noted in AUC (15.6 +/- 2.75 mgl-1, 12.3 +/- 3.04 mg h l-1 and 15.0 +/- 2.06 mgl-1) and in the amount of cumulative urinary excretion (79.2 +/- 11.1 mg, 72.1 +/- 11.2 mg and 80.6 +/- 7.9 mg), respectively.",Interaction between sotalol and an antacid preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),[h·mg] / [l],12.3,40615,DB00489,Sotalol
,9088581,AUC,"A similar significant change was noted in AUC (15.6 +/- 2.75 mgl-1, 12.3 +/- 3.04 mg h l-1 and 15.0 +/- 2.06 mgl-1) and in the amount of cumulative urinary excretion (79.2 +/- 11.1 mg, 72.1 +/- 11.2 mg and 80.6 +/- 7.9 mg), respectively.",Interaction between sotalol and an antacid preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),1/[mgl],15.0,40616,DB00489,Sotalol
,9088581,cumulative urinary excretion,"A similar significant change was noted in AUC (15.6 +/- 2.75 mgl-1, 12.3 +/- 3.04 mg h l-1 and 15.0 +/- 2.06 mgl-1) and in the amount of cumulative urinary excretion (79.2 +/- 11.1 mg, 72.1 +/- 11.2 mg and 80.6 +/- 7.9 mg), respectively.",Interaction between sotalol and an antacid preparation. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),mg,79.2,40617,DB00489,Sotalol
,9088581,cumulative urinary excretion,"A similar significant change was noted in AUC (15.6 +/- 2.75 mgl-1, 12.3 +/- 3.04 mg h l-1 and 15.0 +/- 2.06 mgl-1) and in the amount of cumulative urinary excretion (79.2 +/- 11.1 mg, 72.1 +/- 11.2 mg and 80.6 +/- 7.9 mg), respectively.",Interaction between sotalol and an antacid preparation. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),mg,72.1,40618,DB00489,Sotalol
,9088581,cumulative urinary excretion,"A similar significant change was noted in AUC (15.6 +/- 2.75 mgl-1, 12.3 +/- 3.04 mg h l-1 and 15.0 +/- 2.06 mgl-1) and in the amount of cumulative urinary excretion (79.2 +/- 11.1 mg, 72.1 +/- 11.2 mg and 80.6 +/- 7.9 mg), respectively.",Interaction between sotalol and an antacid preparation. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),mg,80.6,40619,DB00489,Sotalol
,6151871,brain:plasma uptake ratio,"Propranolol, by far the most lipophilic beta-blocker in vitro, had the highest in vivo metabolic clearance and volume of distribution (Vd), the most rapid entry into CSF, and the highest brain:plasma uptake ratio (38.0).","Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6151871/),,38.0,44818,DB00489,Sotalol
,6151871,brain:plasma ratio,"Sotalol, the most hydrophilic drug in vitro, had the lowest in vivo clearance and Vd, the slowest CSF entry, and the lowest brain:plasma ratio (0.52).","Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6151871/),,0.52,44819,DB00489,Sotalol
,6151871,brain:plasma uptake ratio,"Acebutolol had slightly greater in vitro lipophilicity than sotalol, intermediate values of in vivo plasma kinetics and CSF entry rate, and a slightly greater brain:plasma uptake ratio (0.71).","Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6151871/),,0.71,44820,DB00489,Sotalol
,6111331,maximum effect,The maximum effect (34.4 +/- 2.2%) occurred after 40 mg.,"Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111331/),%,34.4,49948,DB00489,Sotalol
,6111331,plasma elimination half-lives,"The plasma elimination half-lives after 10, 20 and 40 mg were 11.4 +/- 2.5, 15.9 +/- 4.9 and 15.1 +/- 3.1 h.","Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111331/),h,11.4,49949,DB00489,Sotalol
,6111331,plasma elimination half-lives,"The plasma elimination half-lives after 10, 20 and 40 mg were 11.4 +/- 2.5, 15.9 +/- 4.9 and 15.1 +/- 3.1 h.","Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111331/),h,15.9,49950,DB00489,Sotalol
,6111331,plasma elimination half-lives,"The plasma elimination half-lives after 10, 20 and 40 mg were 11.4 +/- 2.5, 15.9 +/- 4.9 and 15.1 +/- 3.1 h.","Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111331/),h,15.1,49951,DB00489,Sotalol
,6111331,half-life,The half-life for betaxolol was 24.5 h which was longer than that for any of the other drugs.,"Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111331/),h,24.5,49952,DB00489,Sotalol
,1788167,flow rate,The resulting diastereomers were chromatographed with normal-phase HPLC with chloroform:hexane:methanol [65:33:2 (v/v)] as the mobile phase at a flow rate of 2 ml/min.,Stereospecific high-performance liquid chromatographic assay of sotalol in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788167/),[ml] / [min],2,58285,DB00489,Sotalol
,8951189,half-life,"2. In the single dose studies, the half-life of (-)-sotalol (7.2-8.5 h) was significantly (P < 0.01) shorter than that of (+)-sotalol (9.1-11.4 h) while the renal clearance of (-)-sotalol (110.6-126.4 ml min-1) was significantly (P < 0.01) faster than that of (+)-sotalol (102.2-110.1 ml min-1).",Pharmacokinetics and pharmacodynamics of (+/-)-sotalol in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951189/),h,7.2-8.5,72961,DB00489,Sotalol
,8951189,half-life,"2. In the single dose studies, the half-life of (-)-sotalol (7.2-8.5 h) was significantly (P < 0.01) shorter than that of (+)-sotalol (9.1-11.4 h) while the renal clearance of (-)-sotalol (110.6-126.4 ml min-1) was significantly (P < 0.01) faster than that of (+)-sotalol (102.2-110.1 ml min-1).",Pharmacokinetics and pharmacodynamics of (+/-)-sotalol in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951189/),h,9.1-11.4,72962,DB00489,Sotalol
,8951189,renal clearance,"2. In the single dose studies, the half-life of (-)-sotalol (7.2-8.5 h) was significantly (P < 0.01) shorter than that of (+)-sotalol (9.1-11.4 h) while the renal clearance of (-)-sotalol (110.6-126.4 ml min-1) was significantly (P < 0.01) faster than that of (+)-sotalol (102.2-110.1 ml min-1).",Pharmacokinetics and pharmacodynamics of (+/-)-sotalol in healthy male volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951189/),[ml] / [min],110.6-126.4,72963,DB00489,Sotalol
,8951189,renal clearance,"2. In the single dose studies, the half-life of (-)-sotalol (7.2-8.5 h) was significantly (P < 0.01) shorter than that of (+)-sotalol (9.1-11.4 h) while the renal clearance of (-)-sotalol (110.6-126.4 ml min-1) was significantly (P < 0.01) faster than that of (+)-sotalol (102.2-110.1 ml min-1).",Pharmacokinetics and pharmacodynamics of (+/-)-sotalol in healthy male volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951189/),[ml] / [min],102.2-110.1,72964,DB00489,Sotalol
,8373714,oral clearance,"In all patients studied (n = 7) values of oral clearance (137 +/- 51 ml min-1), renal clearance (96 +/- 42 ml min-1) and nonrenal clearance (41 +/- 25 ml min-1) of (-)-sotalol were greater than those for (+)-sotalol (123 +/- 45 ml min-1, 89 +/- 39 ml min-1 and 34 +/- 23 ml min-1, respectively; P < 0.05, Student's paired t-test).",Stereoselective disposition of (+/-)-sotalol at steady-state conditions. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373714/),[ml] / [min],137,81162,DB00489,Sotalol
,8373714,renal clearance,"In all patients studied (n = 7) values of oral clearance (137 +/- 51 ml min-1), renal clearance (96 +/- 42 ml min-1) and nonrenal clearance (41 +/- 25 ml min-1) of (-)-sotalol were greater than those for (+)-sotalol (123 +/- 45 ml min-1, 89 +/- 39 ml min-1 and 34 +/- 23 ml min-1, respectively; P < 0.05, Student's paired t-test).",Stereoselective disposition of (+/-)-sotalol at steady-state conditions. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373714/),[ml] / [min],96,81163,DB00489,Sotalol
,8373714,renal clearance,"In all patients studied (n = 7) values of oral clearance (137 +/- 51 ml min-1), renal clearance (96 +/- 42 ml min-1) and nonrenal clearance (41 +/- 25 ml min-1) of (-)-sotalol were greater than those for (+)-sotalol (123 +/- 45 ml min-1, 89 +/- 39 ml min-1 and 34 +/- 23 ml min-1, respectively; P < 0.05, Student's paired t-test).",Stereoselective disposition of (+/-)-sotalol at steady-state conditions. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373714/),[ml] / [min],123,81164,DB00489,Sotalol
,8373714,renal clearance,"In all patients studied (n = 7) values of oral clearance (137 +/- 51 ml min-1), renal clearance (96 +/- 42 ml min-1) and nonrenal clearance (41 +/- 25 ml min-1) of (-)-sotalol were greater than those for (+)-sotalol (123 +/- 45 ml min-1, 89 +/- 39 ml min-1 and 34 +/- 23 ml min-1, respectively; P < 0.05, Student's paired t-test).",Stereoselective disposition of (+/-)-sotalol at steady-state conditions. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373714/),[ml] / [min],89,81165,DB00489,Sotalol
,8373714,nonrenal clearance,"In all patients studied (n = 7) values of oral clearance (137 +/- 51 ml min-1), renal clearance (96 +/- 42 ml min-1) and nonrenal clearance (41 +/- 25 ml min-1) of (-)-sotalol were greater than those for (+)-sotalol (123 +/- 45 ml min-1, 89 +/- 39 ml min-1 and 34 +/- 23 ml min-1, respectively; P < 0.05, Student's paired t-test).",Stereoselective disposition of (+/-)-sotalol at steady-state conditions. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373714/),[ml] / [min],41,81166,DB00489,Sotalol
,8373714,unbound nonrenal clearance,"In contrast, estimated unbound nonrenal clearance, which represents approximately 25% of the total unbound clearance of the drug, was greater for the (-)-enantiomer (64 +/- 42 ml min-1) compared with (+)-sotalol (57 +/- 42 ml min-1; P < 0.05).",Stereoselective disposition of (+/-)-sotalol at steady-state conditions. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373714/),[ml] / [min],64,81167,DB00489,Sotalol
,8373714,unbound nonrenal clearance,"In contrast, estimated unbound nonrenal clearance, which represents approximately 25% of the total unbound clearance of the drug, was greater for the (-)-enantiomer (64 +/- 42 ml min-1) compared with (+)-sotalol (57 +/- 42 ml min-1; P < 0.05).",Stereoselective disposition of (+/-)-sotalol at steady-state conditions. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373714/),[ml] / [min],57,81168,DB00489,Sotalol
,12932617,plasma concentration,"The mean fetal/maternal sotalol plasma concentration was 1.1 (range 0.67 to 2.87, SD 0.63), and the mean amniotic fluid/fetal blood ratio of sotalol was 3.2 (range 1.28 to 5.8, SD 1.4).",Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932617/),,1.1,81903,DB00489,Sotalol
,12932617,amniotic fluid/fetal blood ratio,"The mean fetal/maternal sotalol plasma concentration was 1.1 (range 0.67 to 2.87, SD 0.63), and the mean amniotic fluid/fetal blood ratio of sotalol was 3.2 (range 1.28 to 5.8, SD 1.4).",Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932617/),,3.2,81904,DB00489,Sotalol
,14709906,detection limit,The detection limit of sotalol by the enzyme-linked immunosorbent assay was approximately 32 ng/ml with 50-microl samples.,Establishment of an enzyme-linked immunosorbent assay for measurement of sotalol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14709906/),[ng] / [ml],32,85188,DB00489,Sotalol
,8950050,Clb,"Clb for S- and R-STL (0.0675 +/- 0.0090 and 0.0662 +/- 0.0089 mL min-1 kg-1, respectively) represented approximately 0.3% of systemic clearance (Cls) values for S- and R-STL (20.4 +/- 2.2 and 20.7 +/- 2.0 mL min-1 kg-1, respectively).","Renal, biliary and intestinal clearance of sotalol enantiomers in rat model: evidence of intestinal exsorption. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950050/),[ml] / [kg·min],0.0675,89996,DB00489,Sotalol
,8950050,Clb,"Clb for S- and R-STL (0.0675 +/- 0.0090 and 0.0662 +/- 0.0089 mL min-1 kg-1, respectively) represented approximately 0.3% of systemic clearance (Cls) values for S- and R-STL (20.4 +/- 2.2 and 20.7 +/- 2.0 mL min-1 kg-1, respectively).","Renal, biliary and intestinal clearance of sotalol enantiomers in rat model: evidence of intestinal exsorption. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950050/),[ml] / [kg·min],0.0662,89997,DB00489,Sotalol
,8950050,systemic clearance (Cls),"Clb for S- and R-STL (0.0675 +/- 0.0090 and 0.0662 +/- 0.0089 mL min-1 kg-1, respectively) represented approximately 0.3% of systemic clearance (Cls) values for S- and R-STL (20.4 +/- 2.2 and 20.7 +/- 2.0 mL min-1 kg-1, respectively).","Renal, biliary and intestinal clearance of sotalol enantiomers in rat model: evidence of intestinal exsorption. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950050/),[ml] / [kg·min],20.4,89998,DB00489,Sotalol
,8950050,systemic clearance (Cls),"Clb for S- and R-STL (0.0675 +/- 0.0090 and 0.0662 +/- 0.0089 mL min-1 kg-1, respectively) represented approximately 0.3% of systemic clearance (Cls) values for S- and R-STL (20.4 +/- 2.2 and 20.7 +/- 2.0 mL min-1 kg-1, respectively).","Renal, biliary and intestinal clearance of sotalol enantiomers in rat model: evidence of intestinal exsorption. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950050/),[ml] / [kg·min],20.7,89999,DB00489,Sotalol
,8950050,Bile:plasma concentration ratios,"Bile:plasma concentration ratios at 1, 2, and 3 h post-dose were approximately 1.4, 1.3, and 1.2 for both STL enantiomers.","Renal, biliary and intestinal clearance of sotalol enantiomers in rat model: evidence of intestinal exsorption. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950050/),,1.4,90000,DB00489,Sotalol
,8950050,Bile:plasma concentration ratios,"Bile:plasma concentration ratios at 1, 2, and 3 h post-dose were approximately 1.4, 1.3, and 1.2 for both STL enantiomers.","Renal, biliary and intestinal clearance of sotalol enantiomers in rat model: evidence of intestinal exsorption. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950050/),,1.3,90001,DB00489,Sotalol
,8950050,Bile:plasma concentration ratios,"Bile:plasma concentration ratios at 1, 2, and 3 h post-dose were approximately 1.4, 1.3, and 1.2 for both STL enantiomers.","Renal, biliary and intestinal clearance of sotalol enantiomers in rat model: evidence of intestinal exsorption. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950050/),,1.2,90002,DB00489,Sotalol
,8950050,Clr,"STL enantiomers were predominantly eliminated intact in the urine: Clr for S- and R-STL (26.3 +/- 3.2 and 28.7 +/- 4.2 mL min-1 kg-1 respectively) accounted for approximately 96% of Cls for S- and R-STL (27.5 +/- 3.3 and 29.9 +/- 4.2 mL min-1 kg-1, respectively).","Renal, biliary and intestinal clearance of sotalol enantiomers in rat model: evidence of intestinal exsorption. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950050/),[ml] / [kg·min],26.3,90003,DB00489,Sotalol
,8950050,Clr,"STL enantiomers were predominantly eliminated intact in the urine: Clr for S- and R-STL (26.3 +/- 3.2 and 28.7 +/- 4.2 mL min-1 kg-1 respectively) accounted for approximately 96% of Cls for S- and R-STL (27.5 +/- 3.3 and 29.9 +/- 4.2 mL min-1 kg-1, respectively).","Renal, biliary and intestinal clearance of sotalol enantiomers in rat model: evidence of intestinal exsorption. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950050/),[ml] / [kg·min],28.7,90004,DB00489,Sotalol
,8950050,Cls,"STL enantiomers were predominantly eliminated intact in the urine: Clr for S- and R-STL (26.3 +/- 3.2 and 28.7 +/- 4.2 mL min-1 kg-1 respectively) accounted for approximately 96% of Cls for S- and R-STL (27.5 +/- 3.3 and 29.9 +/- 4.2 mL min-1 kg-1, respectively).","Renal, biliary and intestinal clearance of sotalol enantiomers in rat model: evidence of intestinal exsorption. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950050/),[ml] / [kg·min],27.5,90005,DB00489,Sotalol
,8950050,Cls,"STL enantiomers were predominantly eliminated intact in the urine: Clr for S- and R-STL (26.3 +/- 3.2 and 28.7 +/- 4.2 mL min-1 kg-1 respectively) accounted for approximately 96% of Cls for S- and R-STL (27.5 +/- 3.3 and 29.9 +/- 4.2 mL min-1 kg-1, respectively).","Renal, biliary and intestinal clearance of sotalol enantiomers in rat model: evidence of intestinal exsorption. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950050/),[ml] / [kg·min],29.9,90006,DB00489,Sotalol
,8950050,Cli,"Approximately 4% of the dose was recovered in the faeces, corresponding to Cli values of 1.16 +/- 0.17 and 1.26 +/- 0.19 mL min-1 kg-1 for S- and R-STL, respectively.","Renal, biliary and intestinal clearance of sotalol enantiomers in rat model: evidence of intestinal exsorption. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950050/),[ml] / [kg·min],1.16,90007,DB00489,Sotalol
,8950050,Cli,"Approximately 4% of the dose was recovered in the faeces, corresponding to Cli values of 1.16 +/- 0.17 and 1.26 +/- 0.19 mL min-1 kg-1 for S- and R-STL, respectively.","Renal, biliary and intestinal clearance of sotalol enantiomers in rat model: evidence of intestinal exsorption. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950050/),[ml] / [kg·min],1.26,90008,DB00489,Sotalol
,8950050,Total recovery,"Total recovery of the administered dose in urine and faeces was 99.7 +/- 0.2 and 99.8 +/- 0.5% for S- and R-STL, respectively.","Renal, biliary and intestinal clearance of sotalol enantiomers in rat model: evidence of intestinal exsorption. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950050/),%,99.7,90009,DB00489,Sotalol
,8950050,Total recovery,"Total recovery of the administered dose in urine and faeces was 99.7 +/- 0.2 and 99.8 +/- 0.5% for S- and R-STL, respectively.","Renal, biliary and intestinal clearance of sotalol enantiomers in rat model: evidence of intestinal exsorption. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950050/),%,99.8,90010,DB00489,Sotalol
,16628137,flow rate,"Separation was performed on a C18 reverse-phase column (4 microm) using a binary mobile phase consisting of 0.05 M of phosphate buffer, pH 5.5, and methanol (80:20, vol/vol) at a flow rate of 0.7 mL/minute.",A micromethod for the quantification of atenolol in plasma using high-performance liquid chromatography with fluorescence detection: therapeutic drug monitoring of two patients with severe coronary insufficiency before cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628137/),[ml] / [min],0.7,109634,DB00489,Sotalol
,16628137,retention times,"The retention times of atenolol and of the internal standard (sotalol) were 12.7 and 10.4 minutes, respectively.",A micromethod for the quantification of atenolol in plasma using high-performance liquid chromatography with fluorescence detection: therapeutic drug monitoring of two patients with severe coronary insufficiency before cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628137/),min,12.7,109635,DB00489,Sotalol
,16628137,retention times,"The retention times of atenolol and of the internal standard (sotalol) were 12.7 and 10.4 minutes, respectively.",A micromethod for the quantification of atenolol in plasma using high-performance liquid chromatography with fluorescence detection: therapeutic drug monitoring of two patients with severe coronary insufficiency before cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628137/),min,10.4,109636,DB00489,Sotalol
,16628137,Absolute recovery,Absolute recovery was 93.7%.,A micromethod for the quantification of atenolol in plasma using high-performance liquid chromatography with fluorescence detection: therapeutic drug monitoring of two patients with severe coronary insufficiency before cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628137/),%,93.7,109637,DB00489,Sotalol
,9643622,time at which maximum serum concentrations were reached (tmax),"The addition of cisapride decreased the time at which maximum serum concentrations were reached (tmax) from 2.79 (1.85-4.34) h to 1.16 (0.68-2.30) h (P=0.009) [95% CI: -2.59, -0.55] and increased the absorption rate constant (ka) from 0.49 (0.31-0.69) h(-1) to 1.26 (0.52-5.61) h(-1) (P=0.017).",Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643622/),h,2.79,119237,DB00489,Sotalol
,9643622,time at which maximum serum concentrations were reached (tmax),"The addition of cisapride decreased the time at which maximum serum concentrations were reached (tmax) from 2.79 (1.85-4.34) h to 1.16 (0.68-2.30) h (P=0.009) [95% CI: -2.59, -0.55] and increased the absorption rate constant (ka) from 0.49 (0.31-0.69) h(-1) to 1.26 (0.52-5.61) h(-1) (P=0.017).",Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643622/),h,1.16,119238,DB00489,Sotalol
,9643622,absorption rate constant (ka),"The addition of cisapride decreased the time at which maximum serum concentrations were reached (tmax) from 2.79 (1.85-4.34) h to 1.16 (0.68-2.30) h (P=0.009) [95% CI: -2.59, -0.55] and increased the absorption rate constant (ka) from 0.49 (0.31-0.69) h(-1) to 1.26 (0.52-5.61) h(-1) (P=0.017).",Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643622/),1/[h],0.49,119239,DB00489,Sotalol
,9643622,absorption rate constant (ka),"The addition of cisapride decreased the time at which maximum serum concentrations were reached (tmax) from 2.79 (1.85-4.34) h to 1.16 (0.68-2.30) h (P=0.009) [95% CI: -2.59, -0.55] and increased the absorption rate constant (ka) from 0.49 (0.31-0.69) h(-1) to 1.26 (0.52-5.61) h(-1) (P=0.017).",Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643622/),1/[h],1.26,119240,DB00489,Sotalol
,9643622,absolute bioavailability,"The absolute bioavailability of sotalol was reduced by cisapride from 1.00+/-0.15 to 0.70+/-0.26 (P=0.006), while maximum serum concentrations of both oral solutions were not significantly different.",Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643622/),,1.00,119241,DB00489,Sotalol
,9643622,absolute bioavailability,"The absolute bioavailability of sotalol was reduced by cisapride from 1.00+/-0.15 to 0.70+/-0.26 (P=0.006), while maximum serum concentrations of both oral solutions were not significantly different.",Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643622/),,0.70,119242,DB00489,Sotalol
,9643622,tmax,"Compared with the sublingually administered tablet with a median tmax of 2.12 (0.89-3.28) h, the sotalol/cisapride oral solution gave a smaller tmax (p=0.009) [95% CI: -1.64, -0.36].",Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643622/),h,2.12,119243,DB00489,Sotalol
,9643622,ka,The ka of the sotalol/cisapride solution was significantly (P=0.010) larger than the ka of 0.56 (0.33-0.75) h(-1) found after sublingual administration of the tablet.,Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643622/),1/[h],0.56,119244,DB00489,Sotalol
,16198851,trough levels,"In a subgroup of 15 patients, one-half of the patients converted into sinus rhythm at sotalol trough levels of 0.4 mug/ml and more than 95% at 1.0 mug/ml.",Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198851/),[μg] / [ml],0.4,119303,DB00489,Sotalol
,16198851,trough levels,"In a subgroup of 15 patients, one-half of the patients converted into sinus rhythm at sotalol trough levels of 0.4 mug/ml and more than 95% at 1.0 mug/ml.",Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198851/),,1,119304,DB00489,Sotalol
,9017761,elimination half-life,The elimination half-life of ibutilide ranges from 2-12 hours.,Ibutilide: a new class III antiarrhythmic agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9017761/),h,2-12,121444,DB00489,Sotalol
,9017761,time to conversion,The time to conversion in most trials was usually 20-30 minutes.,Ibutilide: a new class III antiarrhythmic agent. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9017761/),min,20-30,121445,DB00489,Sotalol
,13958,t1/2 of distribution,The t1/2 of distribution ranges between 5 to 30 minutes.,Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13958/),min,5 to 30,131024,DB00489,Sotalol
,13958,elimination half-life,The beta-blockers are relatively rapidly eliminated from the body and most of them have an elimination half-life between 2 to 4 hours.,Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/13958/),h,2 to 4,131025,DB00489,Sotalol
,971701,half-life,The half-life of sotalol in plasma was 12.7 +/- SE 1.6 hours.,Observations on the efficacy and pharmacokinetics of sotalol after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971701/),h,12.7,131144,DB00489,Sotalol
,501565,t 1/2,The t 1/2 of this drug (4.30 +/- 0.40 hr) in dogs was longer than that of other beta adrenergic blockers.,Relationship between pharmacokinetics and pharmacodynamics of the beta adrenergic blocking drug sotalol in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/501565/),h,4.30,131631,DB00489,Sotalol
,501565,renal clearance of the drug,The renal clearance of the drug (4.21 +/- 0.31 ml/min/kg) was approximately 90% of total plasma clearance together with an extensive fraction excreted unchanged (72 +/- 12% of dose) in urine.,Relationship between pharmacokinetics and pharmacodynamics of the beta adrenergic blocking drug sotalol in dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/501565/),[ml] / [kg·min],4.21,131632,DB00489,Sotalol
,7439252,serum half-life,"For an anuric patient, serum half-life was calculated to be 69 h.",Pharmacokinetics of sotalol after chronic administration to patients with renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439252/),h,69,132810,DB00489,Sotalol
,26670333,peak plasma concentrations,"Mean peak plasma concentrations after IV and PO administration of STL were 1624 ng/mL and 317 ng/mL, respectively.",Pharmacokinetics of intravenously and orally administered sotalol hydrochloride in horses and effects on surface electrocardiogram and left ventricular systolic function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26670333/),[ng] / [ml],1624,151685,DB00489,Sotalol
,26670333,peak plasma concentrations,"Mean peak plasma concentrations after IV and PO administration of STL were 1624 ng/mL and 317 ng/mL, respectively.",Pharmacokinetics of intravenously and orally administered sotalol hydrochloride in horses and effects on surface electrocardiogram and left ventricular systolic function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26670333/),[ng] / [ml],317,151686,DB00489,Sotalol
,26670333,oral bioavailability,"The oral bioavailability was intermediate (48%) with maximal absorption after 0.94 h, a moderate distribution and a mean elimination half-life of 15.24 h.",Pharmacokinetics of intravenously and orally administered sotalol hydrochloride in horses and effects on surface electrocardiogram and left ventricular systolic function. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26670333/),%,48,151687,DB00489,Sotalol
,26670333,elimination half-life,"The oral bioavailability was intermediate (48%) with maximal absorption after 0.94 h, a moderate distribution and a mean elimination half-life of 15.24 h.",Pharmacokinetics of intravenously and orally administered sotalol hydrochloride in horses and effects on surface electrocardiogram and left ventricular systolic function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26670333/),h,15.24,151688,DB00489,Sotalol
,10657059,flow rate,"R,S-sotalol and its internal standard (atenolol) were eluted after 5.9 and 8.5 min, respectively, from a 4-micron C18 reverse-phase column using a mobile phase consisting of 80 mM KH2PO4, pH 4.6, and acetonitrile (95:5, v/v) at a flow rate of 0.5 ml/min with detection at lambdaex = 235 nm and lambdaem = 310 nm, respectively.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),[ml] / [min],0.5,161467,DB00489,Sotalol
,10657059,C MAX,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),[ng] / [ml],1230,161468,DB00489,Sotalol
,10657059,T MAX,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),h,1.8,161469,DB00489,Sotalol
,10657059,AUC T,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),[ng] / [h·ml],10645,161470,DB00489,Sotalol
,10657059,Kab,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),1/[h],1.23,161471,DB00489,Sotalol
,10657059,alpha,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),1/[h],0.95,161472,DB00489,Sotalol
,10657059,ss,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),1/[h],0.09,161473,DB00489,Sotalol
,10657059,t((1/2))ss,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),h,7.8,161474,DB00489,Sotalol
,10657059,ClT/F,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),[ml] / [kg·min],3.94,161475,DB00489,Sotalol
,10657059,Vd/F,"Data obtained, expressed as mean, were: C MAX = 1230 ng/ml, T MAX = 1.8 h, AUC T = 10645 ng h-1 ml-1, Kab = 1.23 h-1, alpha = 0.95 h-1, ss = 0.09 h-1, t((1/2))ss = 7.8 h, ClT/F = 3.94 ml min-1 kg-1, and Vd/F = 2.53 l/kg.","A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10657059/),[l] / [kg],2.53,161476,DB00489,Sotalol
,1976782,total body clearance,"In obese subjects, the pharmacokinetic data calculated for sotalol were comparable with those measured in controls (total body clearance = 9.4 +/- 2.9 L h-1; volume of distribution during the terminal phase = 79.8 +/- 19.8 L or 0.9 +/- 0.2 L kg-1; terminal half-life = 6.2 +/- 1.6 h).",Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976782/),[l] / [h],9.4,170971,DB00489,Sotalol
,1976782,volume of distribution during the terminal phase,"In obese subjects, the pharmacokinetic data calculated for sotalol were comparable with those measured in controls (total body clearance = 9.4 +/- 2.9 L h-1; volume of distribution during the terminal phase = 79.8 +/- 19.8 L or 0.9 +/- 0.2 L kg-1; terminal half-life = 6.2 +/- 1.6 h).",Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976782/),l,79.8,170972,DB00489,Sotalol
,1976782,volume of distribution during the terminal phase,"In obese subjects, the pharmacokinetic data calculated for sotalol were comparable with those measured in controls (total body clearance = 9.4 +/- 2.9 L h-1; volume of distribution during the terminal phase = 79.8 +/- 19.8 L or 0.9 +/- 0.2 L kg-1; terminal half-life = 6.2 +/- 1.6 h).",Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976782/),[l] / [kg],0.9,170973,DB00489,Sotalol
,1976782,terminal half-life,"In obese subjects, the pharmacokinetic data calculated for sotalol were comparable with those measured in controls (total body clearance = 9.4 +/- 2.9 L h-1; volume of distribution during the terminal phase = 79.8 +/- 19.8 L or 0.9 +/- 0.2 L kg-1; terminal half-life = 6.2 +/- 1.6 h).",Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976782/),h,6.2,170974,DB00489,Sotalol
,1976782,total clearance,"For propranolol, total clearance (44.3 +/- 15.9 L h-1) and volume of distribution (230.5 +/- 48.2 L or 2.7 +/- 0.7 L kg-1) were significantly less than control values.",Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976782/),[l] / [h],44.3,170975,DB00489,Sotalol
,1976782,volume of distribution,"For propranolol, total clearance (44.3 +/- 15.9 L h-1) and volume of distribution (230.5 +/- 48.2 L or 2.7 +/- 0.7 L kg-1) were significantly less than control values.",Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976782/),l,230.5,170976,DB00489,Sotalol
,1976782,volume of distribution,"For propranolol, total clearance (44.3 +/- 15.9 L h-1) and volume of distribution (230.5 +/- 48.2 L or 2.7 +/- 0.7 L kg-1) were significantly less than control values.",Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976782/),[l] / [kg],2.7,170977,DB00489,Sotalol
,1976782,terminal half-life,"The terminal half-life (3.9 +/- 1.1 h), was not significantly increased.",Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976782/),h,3.9,170978,DB00489,Sotalol
,12064057,CSSMAX,"A one open compartment model was applied and the main pharmacokinetic parameters obtained for R-/S-sotalol were, respectively (Mean +/- SD): CSSMAX = 1007 +/- 307/1040 +/- 340 ng/mL; TMAX = 1.82 +/- 0.6/1.83 +/- 0.6 h; AUCSST = 6959 +/- 2153/7388 +/- 2563 ng.h/mL; CISSr/F = 2.7 +/- 1.2/2.5 +/- 1.2 mL/min/kg and VdSS/F = 1.9 +/- 0.9/2.0 +/- 1.0 L/kg.",Kinetic disposition of (+)-S- and (-)-R-sotalol enantiomers in cardiac patients with tachyarrhythmias using an improved HPLC-fluorescence stereoselective method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12064057/),[ng] / [ml],1007,174738,DB00489,Sotalol
,12064057,CSSMAX,"A one open compartment model was applied and the main pharmacokinetic parameters obtained for R-/S-sotalol were, respectively (Mean +/- SD): CSSMAX = 1007 +/- 307/1040 +/- 340 ng/mL; TMAX = 1.82 +/- 0.6/1.83 +/- 0.6 h; AUCSST = 6959 +/- 2153/7388 +/- 2563 ng.h/mL; CISSr/F = 2.7 +/- 1.2/2.5 +/- 1.2 mL/min/kg and VdSS/F = 1.9 +/- 0.9/2.0 +/- 1.0 L/kg.",Kinetic disposition of (+)-S- and (-)-R-sotalol enantiomers in cardiac patients with tachyarrhythmias using an improved HPLC-fluorescence stereoselective method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12064057/),[ng] / [ml],1040,174739,DB00489,Sotalol
,12064057,TMAX,"A one open compartment model was applied and the main pharmacokinetic parameters obtained for R-/S-sotalol were, respectively (Mean +/- SD): CSSMAX = 1007 +/- 307/1040 +/- 340 ng/mL; TMAX = 1.82 +/- 0.6/1.83 +/- 0.6 h; AUCSST = 6959 +/- 2153/7388 +/- 2563 ng.h/mL; CISSr/F = 2.7 +/- 1.2/2.5 +/- 1.2 mL/min/kg and VdSS/F = 1.9 +/- 0.9/2.0 +/- 1.0 L/kg.",Kinetic disposition of (+)-S- and (-)-R-sotalol enantiomers in cardiac patients with tachyarrhythmias using an improved HPLC-fluorescence stereoselective method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12064057/),h,1.82,174740,DB00489,Sotalol
,12064057,TMAX,"A one open compartment model was applied and the main pharmacokinetic parameters obtained for R-/S-sotalol were, respectively (Mean +/- SD): CSSMAX = 1007 +/- 307/1040 +/- 340 ng/mL; TMAX = 1.82 +/- 0.6/1.83 +/- 0.6 h; AUCSST = 6959 +/- 2153/7388 +/- 2563 ng.h/mL; CISSr/F = 2.7 +/- 1.2/2.5 +/- 1.2 mL/min/kg and VdSS/F = 1.9 +/- 0.9/2.0 +/- 1.0 L/kg.",Kinetic disposition of (+)-S- and (-)-R-sotalol enantiomers in cardiac patients with tachyarrhythmias using an improved HPLC-fluorescence stereoselective method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12064057/),h,1.83,174741,DB00489,Sotalol
,12064057,AUCSST,"A one open compartment model was applied and the main pharmacokinetic parameters obtained for R-/S-sotalol were, respectively (Mean +/- SD): CSSMAX = 1007 +/- 307/1040 +/- 340 ng/mL; TMAX = 1.82 +/- 0.6/1.83 +/- 0.6 h; AUCSST = 6959 +/- 2153/7388 +/- 2563 ng.h/mL; CISSr/F = 2.7 +/- 1.2/2.5 +/- 1.2 mL/min/kg and VdSS/F = 1.9 +/- 0.9/2.0 +/- 1.0 L/kg.",Kinetic disposition of (+)-S- and (-)-R-sotalol enantiomers in cardiac patients with tachyarrhythmias using an improved HPLC-fluorescence stereoselective method. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12064057/),[h·ng] / [ml],6959,174742,DB00489,Sotalol
,12064057,AUCSST,"A one open compartment model was applied and the main pharmacokinetic parameters obtained for R-/S-sotalol were, respectively (Mean +/- SD): CSSMAX = 1007 +/- 307/1040 +/- 340 ng/mL; TMAX = 1.82 +/- 0.6/1.83 +/- 0.6 h; AUCSST = 6959 +/- 2153/7388 +/- 2563 ng.h/mL; CISSr/F = 2.7 +/- 1.2/2.5 +/- 1.2 mL/min/kg and VdSS/F = 1.9 +/- 0.9/2.0 +/- 1.0 L/kg.",Kinetic disposition of (+)-S- and (-)-R-sotalol enantiomers in cardiac patients with tachyarrhythmias using an improved HPLC-fluorescence stereoselective method. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12064057/),[h·ng] / [ml],7388,174743,DB00489,Sotalol
,12064057,CISSr/F,"A one open compartment model was applied and the main pharmacokinetic parameters obtained for R-/S-sotalol were, respectively (Mean +/- SD): CSSMAX = 1007 +/- 307/1040 +/- 340 ng/mL; TMAX = 1.82 +/- 0.6/1.83 +/- 0.6 h; AUCSST = 6959 +/- 2153/7388 +/- 2563 ng.h/mL; CISSr/F = 2.7 +/- 1.2/2.5 +/- 1.2 mL/min/kg and VdSS/F = 1.9 +/- 0.9/2.0 +/- 1.0 L/kg.",Kinetic disposition of (+)-S- and (-)-R-sotalol enantiomers in cardiac patients with tachyarrhythmias using an improved HPLC-fluorescence stereoselective method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12064057/),[ml] / [kg·min],2.7,174744,DB00489,Sotalol
,12064057,CISSr/F,"A one open compartment model was applied and the main pharmacokinetic parameters obtained for R-/S-sotalol were, respectively (Mean +/- SD): CSSMAX = 1007 +/- 307/1040 +/- 340 ng/mL; TMAX = 1.82 +/- 0.6/1.83 +/- 0.6 h; AUCSST = 6959 +/- 2153/7388 +/- 2563 ng.h/mL; CISSr/F = 2.7 +/- 1.2/2.5 +/- 1.2 mL/min/kg and VdSS/F = 1.9 +/- 0.9/2.0 +/- 1.0 L/kg.",Kinetic disposition of (+)-S- and (-)-R-sotalol enantiomers in cardiac patients with tachyarrhythmias using an improved HPLC-fluorescence stereoselective method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12064057/),[ml] / [kg·min],2.5,174745,DB00489,Sotalol
,12064057,VdSS/F,"A one open compartment model was applied and the main pharmacokinetic parameters obtained for R-/S-sotalol were, respectively (Mean +/- SD): CSSMAX = 1007 +/- 307/1040 +/- 340 ng/mL; TMAX = 1.82 +/- 0.6/1.83 +/- 0.6 h; AUCSST = 6959 +/- 2153/7388 +/- 2563 ng.h/mL; CISSr/F = 2.7 +/- 1.2/2.5 +/- 1.2 mL/min/kg and VdSS/F = 1.9 +/- 0.9/2.0 +/- 1.0 L/kg.",Kinetic disposition of (+)-S- and (-)-R-sotalol enantiomers in cardiac patients with tachyarrhythmias using an improved HPLC-fluorescence stereoselective method. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12064057/),[l] / [kg],1.9,174746,DB00489,Sotalol
,12064057,VdSS/F,"A one open compartment model was applied and the main pharmacokinetic parameters obtained for R-/S-sotalol were, respectively (Mean +/- SD): CSSMAX = 1007 +/- 307/1040 +/- 340 ng/mL; TMAX = 1.82 +/- 0.6/1.83 +/- 0.6 h; AUCSST = 6959 +/- 2153/7388 +/- 2563 ng.h/mL; CISSr/F = 2.7 +/- 1.2/2.5 +/- 1.2 mL/min/kg and VdSS/F = 1.9 +/- 0.9/2.0 +/- 1.0 L/kg.",Kinetic disposition of (+)-S- and (-)-R-sotalol enantiomers in cardiac patients with tachyarrhythmias using an improved HPLC-fluorescence stereoselective method. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12064057/),[l] / [kg],2.0,174747,DB00489,Sotalol
,7996391,half-life,The plasma concentration of (+)-sotalol peaked about 3 h after oral administration and declined with a half-life of 7.9-9.7 h.,Comparative pharmacokinetic and pharmacodynamic properties of oral and intravenous (+)-sotalol in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996391/),h,7.9-9.7,176899,DB00489,Sotalol
,7996391,terminal half-life,"After intravenous administration, (+)-sotalol in plasma decreased bi-exponentially with a terminal half-life of 7.6-8.3 h and the urinary recovery as unchanged drug amounted to 84-88% of the dose.",Comparative pharmacokinetic and pharmacodynamic properties of oral and intravenous (+)-sotalol in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996391/),h,7.6-8.3,176900,DB00489,Sotalol
,23819796,Cmax,"Peak rac-sotalol plasma concentration was higher in women than in men (mean Cmax 1.8 μg ml(-1) (range 1.1-2.8) vs. 1.4 μg ml(-1) (range 0.9-1.9), P = 0.0009).",Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23819796/),[μg] / [ml],1.8,178375,DB00489,Sotalol
,23819796,Cmax,"Peak rac-sotalol plasma concentration was higher in women than in men (mean Cmax 1.8 μg ml(-1) (range 1.1-2.8) vs. 1.4 μg ml(-1) (range 0.9-1.9), P = 0.0009).",Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23819796/),[μg] / [ml],1.4,178376,DB00489,Sotalol
,11258173,absolute bioavailability,Moxifloxacin has an absolute bioavailability of 90% after oral administration and a mean elimination half-life of 12 hours.,Moxifloxacin: clinical efficacy and safety. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258173/),%,90,180720,DB00489,Sotalol
,11258173,elimination half-life,Moxifloxacin has an absolute bioavailability of 90% after oral administration and a mean elimination half-life of 12 hours.,Moxifloxacin: clinical efficacy and safety. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258173/),h,12,180721,DB00489,Sotalol
,7904936,apparent elimination half-life,"Following oral administration, absorption and bioavailability are almost complete; apparent elimination half-life ranges from 7 to 18 hours.","Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7904936/),h,7 to 18,181925,DB00489,Sotalol
,15908287,recoveries,"The method was linear for tramadol (3-768 ng/ml) and ODT (1.5-384 ng/ml) with mean recoveries of 87.2% and 89.8%, respectively.",Improved HPLC method for the simultaneous determination of tramadol and O-desmethyltramadol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908287/),%,87.2,182040,DB00489,Sotalol
,15908287,recoveries,"The method was linear for tramadol (3-768 ng/ml) and ODT (1.5-384 ng/ml) with mean recoveries of 87.2% and 89.8%, respectively.",Improved HPLC method for the simultaneous determination of tramadol and O-desmethyltramadol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908287/),%,89.8,182041,DB00489,Sotalol
,6092287,half-life,"When given in repeated doses from 6 h on, 50 g followed by 12.5 g at 6 h intervals, charcoal shortened the half-life after sotalol in serum from 9.4 +/- 0.4 h to 7.6 +/- 0.3 h and in urine from 9.4 +/- 0.4 h to 7.3 +/- 0.3 h (p less than 0.01).",Effect of oral charcoal and urine pH on sotalol pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6092287/),h,9.4,182812,DB00489,Sotalol
,6092287,half-life,"When given in repeated doses from 6 h on, 50 g followed by 12.5 g at 6 h intervals, charcoal shortened the half-life after sotalol in serum from 9.4 +/- 0.4 h to 7.6 +/- 0.3 h and in urine from 9.4 +/- 0.4 h to 7.3 +/- 0.3 h (p less than 0.01).",Effect of oral charcoal and urine pH on sotalol pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6092287/),h,7.6,182813,DB00489,Sotalol
,6092287,half-life,"When given in repeated doses from 6 h on, 50 g followed by 12.5 g at 6 h intervals, charcoal shortened the half-life after sotalol in serum from 9.4 +/- 0.4 h to 7.6 +/- 0.3 h and in urine from 9.4 +/- 0.4 h to 7.3 +/- 0.3 h (p less than 0.01).",Effect of oral charcoal and urine pH on sotalol pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6092287/),h,7.3,182814,DB00489,Sotalol
,3382466,Recovery,Recovery was between 82 and 98% from plasma and between 92 and 99% from urine.,Determination of sotalol in human body fluids for pharmacokinetic and toxicokinetic studies using high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3382466/),%,82 and 98,185902,DB00489,Sotalol
,3382466,Recovery,Recovery was between 82 and 98% from plasma and between 92 and 99% from urine.,Determination of sotalol in human body fluids for pharmacokinetic and toxicokinetic studies using high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3382466/),%,92 and 99,185903,DB00489,Sotalol
,14567646,Cmax,Cmax (185.1 +/- 56.8 ng/ml) was reached at hour 3.,Iontophoretic in vivo transdermal delivery of beta-blockers in hairless rats and reduced skin irritation by liposomal formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14567646/),[ng] / [ml],185.1,192387,DB00489,Sotalol
,9549633,steady-state volume of distribution,"However, women were found to have a lower steady-state volume of distribution than men (1.20 L/Kg versus 1.43 L/Kg).",A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549633/),[l] / [kg],1.20,192678,DB00489,Sotalol
,9549633,steady-state volume of distribution,"However, women were found to have a lower steady-state volume of distribution than men (1.20 L/Kg versus 1.43 L/Kg).",A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549633/),[l] / [kg],1.43,192679,DB00489,Sotalol
,9549633,Q-Tc,"The baseline Q-Tc, determined from the fittings, was found to be significantly higher in women (0.40 versus 0.38 seconds).",A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549633/),seconds,0.40,192680,DB00489,Sotalol
,9549633,Q-Tc,"The baseline Q-Tc, determined from the fittings, was found to be significantly higher in women (0.40 versus 0.38 seconds).",A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549633/),seconds,0.38,192681,DB00489,Sotalol
,9549633,effect compartment clearance,"The effect compartment clearance was found to be highly variable, with a median of 12.3 (range, 0.2-671,300) L/h.",A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549633/),[l] / [h],12.3,192682,DB00489,Sotalol
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,6.1,192732,DB00489,Sotalol
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,7.1,192733,DB00489,Sotalol
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,26.5,192734,DB00489,Sotalol
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,16.7,192735,DB00489,Sotalol
,34287102,metabolic ratio,"M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal.",Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),,0.12,192736,DB00489,Sotalol
,34287102,metabolic ratio,"M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal.",Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),,197,192737,DB00489,Sotalol
,11144992,half-life,The elimination of sotalol was characterized by an average half-life of between 7.4 and 9.2 hours in the four age groups.,Single-dose pharmacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144992/),h,7.4 and 9.2,195657,DB00489,Sotalol
,1279313,elimination half-life,The drug has an elimination half-life of 10-15 h.,Antiarrhythmic actions of DL-sotalol in ventricular and supraventricular arrhythmias. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1279313/),h,10-15,212532,DB00489,Sotalol
,9220045,half-lives,"Logarithmic transformation of the concentration data indicated two separate monoexponential phases in the elimination curve, with half-lives of 30.1 and 11.6 hours.",Pharmacokinetic evaluation of a case of massive sotalol intoxication. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9220045/),h,30.1,220315,DB00489,Sotalol
,9220045,half-lives,"Logarithmic transformation of the concentration data indicated two separate monoexponential phases in the elimination curve, with half-lives of 30.1 and 11.6 hours.",Pharmacokinetic evaluation of a case of massive sotalol intoxication. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9220045/),h,11.6,220316,DB00489,Sotalol
,6861867,systemic clearance,The systemic clearance of sotalol was significantly greater in the antenatal period (2.4 +/- 0.3 ml/min/kg) than in the post-natal phase (1.5 +/- 0.1 ml/min/kg).,Pharmacokinetics of sotalol during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861867/),[ml] / [kg·min],2.4,220363,DB00489,Sotalol
,6861867,systemic clearance,The systemic clearance of sotalol was significantly greater in the antenatal period (2.4 +/- 0.3 ml/min/kg) than in the post-natal phase (1.5 +/- 0.1 ml/min/kg).,Pharmacokinetics of sotalol during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861867/),[ml] / [kg·min],1.5,220364,DB00489,Sotalol
,6861867,elimination half-life,The apparent volume of distribution was similar in the two periods: the elimination half-life was 6.6 +/- 0.6 h ante-natally and 9.3 +/- 0.7 h post-natally after intravenous drug but the trend for faster elimination was not significant.,Pharmacokinetics of sotalol during pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861867/),h,6.6,220365,DB00489,Sotalol
,6861867,elimination half-life,The apparent volume of distribution was similar in the two periods: the elimination half-life was 6.6 +/- 0.6 h ante-natally and 9.3 +/- 0.7 h post-natally after intravenous drug but the trend for faster elimination was not significant.,Pharmacokinetics of sotalol during pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861867/),h,9.3,220366,DB00489,Sotalol
,6861867,elimination half-life,The elimination half-life after oral administration (about 10 h) and bioavailability (about 90%) were not altered significantly by pregnancy.,Pharmacokinetics of sotalol during pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861867/),h,10,220367,DB00489,Sotalol
,6861867,bioavailability,The elimination half-life after oral administration (about 10 h) and bioavailability (about 90%) were not altered significantly by pregnancy.,Pharmacokinetics of sotalol during pregnancy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861867/),%,90,220368,DB00489,Sotalol
,29023952,steady-state plasma concentrations,"Calculated mean steady-state plasma concentrations determined by nonlinear mixed-effect modelling were 287 (range 234-339), 409 (359-458) and 543 (439-646) ng/mL for 2, 3 and 4 mg/kg bwt sotalol PO bid respectively.",Pharmacokinetics and electrophysiological effects of sotalol hydrochloride in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023952/),[ng] / [ml],287,221360,DB00489,Sotalol
,29023952,steady-state plasma concentrations,"Calculated mean steady-state plasma concentrations determined by nonlinear mixed-effect modelling were 287 (range 234-339), 409 (359-458) and 543 (439-646) ng/mL for 2, 3 and 4 mg/kg bwt sotalol PO bid respectively.",Pharmacokinetics and electrophysiological effects of sotalol hydrochloride in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023952/),[ng] / [ml],409,221361,DB00489,Sotalol
,29023952,steady-state plasma concentrations,"Calculated mean steady-state plasma concentrations determined by nonlinear mixed-effect modelling were 287 (range 234-339), 409 (359-458) and 543 (439-646) ng/mL for 2, 3 and 4 mg/kg bwt sotalol PO bid respectively.",Pharmacokinetics and electrophysiological effects of sotalol hydrochloride in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023952/),[ng] / [ml],543,221362,DB00489,Sotalol
,1487548,area under the time-concentration curves,"The area under the time-concentration curves (mean +/- standard deviation [SD]) were 6.95 +/- 0.85 and 6.76 +/- 1.2 (mg/L)hour for S- and R-STL, respectively.",Pharmacokinetics of sotalol enantiomers in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487548/),h,6.95,222346,DB00489,Sotalol
,1487548,area under the time-concentration curves,"The area under the time-concentration curves (mean +/- standard deviation [SD]) were 6.95 +/- 0.85 and 6.76 +/- 1.2 (mg/L)hour for S- and R-STL, respectively.",Pharmacokinetics of sotalol enantiomers in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487548/),h,6.76,222347,DB00489,Sotalol
,1487548,Maximal plasma concentrations,"Maximal plasma concentrations of S- and R-STL were 615 +/- 167 and 619 +/- 164 ng/mL, respectively, which were obtained on average, 3.13 +/- 0.60 hours after dosing.",Pharmacokinetics of sotalol enantiomers in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487548/),[ng] / [ml],615,222348,DB00489,Sotalol
,1487548,Maximal plasma concentrations,"Maximal plasma concentrations of S- and R-STL were 615 +/- 167 and 619 +/- 164 ng/mL, respectively, which were obtained on average, 3.13 +/- 0.60 hours after dosing.",Pharmacokinetics of sotalol enantiomers in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487548/),[ng] / [ml],619,222349,DB00489,Sotalol
,1487548,mean residence time,"The mean residence time (mean +/- SD) was 13.2 +/- 1.2 and 12.9 +/- 1.8 hours for S- and R-STL, respectively.",Pharmacokinetics of sotalol enantiomers in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487548/),h,13.2,222350,DB00489,Sotalol
,1487548,mean residence time,"The mean residence time (mean +/- SD) was 13.2 +/- 1.2 and 12.9 +/- 1.8 hours for S- and R-STL, respectively.",Pharmacokinetics of sotalol enantiomers in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487548/),h,12.9,222351,DB00489,Sotalol
,1487548,renal clearance,"Respective renal clearance values for S- and R-STL were 8.98 +/- 1.5 and 9.46 +/- 2.3 L/hour, and were approximately 1.5 times greater than creatinine clearance.",Pharmacokinetics of sotalol enantiomers in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487548/),[l] / [h],8.98,222352,DB00489,Sotalol
,1487548,renal clearance,"Respective renal clearance values for S- and R-STL were 8.98 +/- 1.5 and 9.46 +/- 2.3 L/hour, and were approximately 1.5 times greater than creatinine clearance.",Pharmacokinetics of sotalol enantiomers in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487548/),[l] / [h],9.46,222353,DB00489,Sotalol
,20562595,Cmax,"Intravenous sotalol administered over 2.5 hours resulted in a significantly greater Cmax than oral administration (830 +/- 391 vs. 601 +/- 289 ng/mL, P < 0.001).",Developing a safe intravenous sotalol dosing regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20562595/),[ng] / [ml],830,222470,DB00489,Sotalol
,20562595,Cmax,"Intravenous sotalol administered over 2.5 hours resulted in a significantly greater Cmax than oral administration (830 +/- 391 vs. 601 +/- 289 ng/mL, P < 0.001).",Developing a safe intravenous sotalol dosing regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20562595/),[ng] / [ml],601,222471,DB00489,Sotalol
,2373132,terminal half-life,"The terminal half-life averaged 7.2 h, and the kinetics was linear, with a mean total clearance of 0.13 l.h-1.kg-1.","The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373132/),h,7.2,222833,DB00489,Sotalol
,2373132,total clearance,"The terminal half-life averaged 7.2 h, and the kinetics was linear, with a mean total clearance of 0.13 l.h-1.kg-1.","The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373132/),[l] / [h·kg],0.13,222834,DB00489,Sotalol
,2373132,absolute systemic availability,The absolute systemic availability of oral d-sotalol was close to 100% and the elimination half-life of the oral-d-enantiomer was similar to that of the i.v. form (7.5 h).,"The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373132/),%,100,222835,DB00489,Sotalol
,2373132,elimination half-life,The absolute systemic availability of oral d-sotalol was close to 100% and the elimination half-life of the oral-d-enantiomer was similar to that of the i.v. form (7.5 h).,"The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373132/),h,7.5,222836,DB00489,Sotalol
,489770,biological half-life,The processes of distribution and elimination are of first order; the intravenous biological half-life is 6 to 8 hours.,Studies on the pharmacokinetics and pharmacodynamics of the beta-adrenergic blocking agent sotalol in normal man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/489770/),h,6 to 8,222857,DB00489,Sotalol
,14552815,limits of quantitation (,The limits of quantitation (LOQ) reached 4 ng/ml for both sotalol enantiomers.,Enantioselective liquid chromatographic-electrospray mass spectrometric assay of beta-adrenergic blockers: application to a pharmacokinetic study of sotalol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14552815/),[ng] / [ml],4,239957,DB00489,Sotalol
,15758,Plasma half-life,"2. Plasma half-life is between 2 and 4 h, except for sotalol (10-12 h).",Pharmacokinetics of beta-receptor-blocking agents in relation to their anti-hypertensive effect. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15758/),h,2 and 4,241317,DB00489,Sotalol
,15758,Plasma half-life,"2. Plasma half-life is between 2 and 4 h, except for sotalol (10-12 h).",Pharmacokinetics of beta-receptor-blocking agents in relation to their anti-hypertensive effect. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15758/),h,10-12,241318,DB00489,Sotalol
,8346722,absolute bioavailability,"As a result, its absolute bioavailability is 90-100%.",Clinical pharmacokinetics of sotalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346722/),%,90-100,257959,DB00489,Sotalol
,8346722,apparent volume of distribution,The drug has an apparent volume of distribution of 1.2-2.4 liters/kg.,Clinical pharmacokinetics of sotalol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346722/),[l] / [kg],1.2-2.4,257960,DB00489,Sotalol
,8346722,total body clearance,"In subjects with normal renal function, total body clearance of sotalol averages 150 mL/min and the terminal elimination half-life is 10-20 hours.",Clinical pharmacokinetics of sotalol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346722/),[ml] / [min],150,257961,DB00489,Sotalol
,8346722,terminal elimination half-life,"In subjects with normal renal function, total body clearance of sotalol averages 150 mL/min and the terminal elimination half-life is 10-20 hours.",Clinical pharmacokinetics of sotalol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346722/),h,10-20,257962,DB00489,Sotalol
,2403731,bioavailability,"Consequently, bioavailability is close to 100%.","Pharmacology, pharmacodynamics and pharmacokinetics of sotalol. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403731/),%,100,258292,DB00489,Sotalol
,2403731,Cmax,Cmax of sotalol is 2 to 3 hours with a t1/2 between 7 and 15 hours.,"Pharmacology, pharmacodynamics and pharmacokinetics of sotalol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403731/),h,2 to 3,258293,DB00489,Sotalol
,2403731,t1/2,Cmax of sotalol is 2 to 3 hours with a t1/2 between 7 and 15 hours.,"Pharmacology, pharmacodynamics and pharmacokinetics of sotalol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403731/),h,7 and 15,258294,DB00489,Sotalol
